A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

Clinical trial NCT05579691 · COMPLETED

Trial details

NCT number: NCT05579691
Sponsor: Larimar Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Friedreich Ataxia

Start date: 2022-09-21
Primary completion: 2023-12-04
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.